MARKET INTRODUCTION
Advanced non-small cell lung carcinoma is a kind of epithelial lung cancer which accounts for 85% of lung cancers. The types of advanced NSCLC are, lung adenocarcinoma, large cell lung carcinoma, and squamous cell- lung carcinoma. Generally advanced NSCLC are insensitive to chemotherapy regiment hence the condition is treated by surgery resection and tyrosine kinase inhibitors such as, gefitinib, erlotinib, icotinib.
MARKET DYNAMICS
The key market drivers for EGFR-TKI for Advanced NSCLC Market are, rising prevalence of solid tumors, cancers, lung cancers across the globe along with increasing healthcare expenditure. Moreover, R&D investments by drug companies to develop and launch novel drug therapies is also expected to fuel market growth. However, high cost involved in overall treatment is expected to restrain market growth during forecast period.
MARKET SCOPE
The "EGFR-TKI for Advanced NSCLC Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of EGFR-TKI for Advanced NSCLC market with detailed market segmentation by type, therapy type and end user. The EGFR-TKI for Advanced NSCLC Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in EGFR-TKI for Advanced NSCLC Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The EGFR-TKI for Advanced NSCLC Market is segmented on the basis of type, therapy type and end user. On the basis of type the market is bifurcated as, gefitinib, erlotinib, afatinib, icotinib. On the basis of therapy type the market is segmented as, mono therapy, combination therapy. And on the basis of end user the market is segmented as, hospitals, cancer centers and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the EGFR-TKI for Advanced NSCLC Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The EGFR-TKI for Advanced NSCLC Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting EGFR-TKI for Advanced NSCLC Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the EGFR-TKI for Advanced NSCLC Market in these regions.
MARKET PLAYERS
The report covers key developments in the EGFR-TKI for Advanced NSCLC Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from EGFR-TKI for Advanced NSCLC Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, EGFR-TKI for Advanced NSCLC market in the global market. Below mentioned is the list of few companies engaged in the EGFR-TKI for Advanced NSCLC Market.
The report also includes the profiles of key players in EGFR-TKI for Advanced NSCLC Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- Beta Pharma Ltd.
- Actiza Pharmaceuticals
- AstraZeneca
- Sun Pharmaceuticals
- Roche
- Teva Pharmaceutical Industries.
- Armas Pharmaceuticals, Inc.
- Boehringer Ingelheim
- Rewine Pharmaceutical
- MSN Laboratories
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. PUBLISHERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 EGFR-TKI For Advanced NSCLC Market - By Type
1.3.2 EGFR-TKI For Advanced NSCLC Market - By Therapy Type
1.3.3 EGFR-TKI For Advanced NSCLC Market - By End User
1.3.4 EGFR-TKI For Advanced NSCLC Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. EGFR-TKI FOR ADVANCED NSCLC MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. EGFR-TKI FOR ADVANCED NSCLC MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. EGFR-TKI FOR ADVANCED NSCLC MARKET - GLOBAL MARKET ANALYSIS
6.1. EGFR-TKI FOR ADVANCED NSCLC - GLOBAL MARKET OVERVIEW
6.2. EGFR-TKI FOR ADVANCED NSCLC - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. EGFR-TKI FOR ADVANCED NSCLC MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. GEFITINIB
7.3.1. Overview
7.3.2. Gefitinib Market Forecast and Analysis
7.4. ERLOTINIB
7.4.1. Overview
7.4.2. Erlotinib Market Forecast and Analysis
7.5. AFATINIB
7.5.1. Overview
7.5.2. Afatinib Market Forecast and Analysis
7.6. ICOTINIB
7.6.1. Overview
7.6.2. Icotinib Market Forecast and Analysis
8. EGFR-TKI FOR ADVANCED NSCLC MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY TYPE
8.1. OVERVIEW
8.2. THERAPY TYPE MARKET FORECASTS AND ANALYSIS
8.3. MONO THERAPY
8.3.1. Overview
8.3.2. Mono therapy Market Forecast and Analysis
8.4. COMBINATION THERAPY
8.4.1. Overview
8.4.2. Combination Therapy Market Forecast and Analysis
9. EGFR-TKI FOR ADVANCED NSCLC MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CANCER CENTERS
9.4.1. Overview
9.4.2. Cancer Centers Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. EGFR-TKI FOR ADVANCED NSCLC MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America EGFR-TKI For Advanced NSCLC Market Overview
10.1.2 North America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis
10.1.3 North America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Type
10.1.4 North America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Therapy Type
10.1.5 North America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By End User
10.1.6 North America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Countries
10.1.6.1 United States EGFR-TKI For Advanced NSCLC Market
10.1.6.1.1 United States EGFR-TKI For Advanced NSCLC Market by Type
10.1.6.1.2 United States EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.1.6.1.3 United States EGFR-TKI For Advanced NSCLC Market by End User
10.1.6.2 Canada EGFR-TKI For Advanced NSCLC Market
10.1.6.2.1 Canada EGFR-TKI For Advanced NSCLC Market by Type
10.1.6.2.2 Canada EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.1.6.2.3 Canada EGFR-TKI For Advanced NSCLC Market by End User
10.1.6.3 Mexico EGFR-TKI For Advanced NSCLC Market
10.1.6.3.1 Mexico EGFR-TKI For Advanced NSCLC Market by Type
10.1.6.3.2 Mexico EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.1.6.3.3 Mexico EGFR-TKI For Advanced NSCLC Market by End User
10.2. EUROPE
10.2.1 Europe EGFR-TKI For Advanced NSCLC Market Overview
10.2.2 Europe EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis
10.2.3 Europe EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Type
10.2.4 Europe EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Therapy Type
10.2.5 Europe EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By End User
10.2.6 Europe EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Countries
10.2.6.1 Germany EGFR-TKI For Advanced NSCLC Market
10.2.6.1.1 Germany EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.1.2 Germany EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.1.3 Germany EGFR-TKI For Advanced NSCLC Market by End User
10.2.6.2 France EGFR-TKI For Advanced NSCLC Market
10.2.6.2.1 France EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.2.2 France EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.2.3 France EGFR-TKI For Advanced NSCLC Market by End User
10.2.6.3 Italy EGFR-TKI For Advanced NSCLC Market
10.2.6.3.1 Italy EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.3.2 Italy EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.3.3 Italy EGFR-TKI For Advanced NSCLC Market by End User
10.2.6.4 Spain EGFR-TKI For Advanced NSCLC Market
10.2.6.4.1 Spain EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.4.2 Spain EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.4.3 Spain EGFR-TKI For Advanced NSCLC Market by End User
10.2.6.5 United Kingdom EGFR-TKI For Advanced NSCLC Market
10.2.6.5.1 United Kingdom EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.5.2 United Kingdom EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.5.3 United Kingdom EGFR-TKI For Advanced NSCLC Market by End User
10.2.6.6 Rest of Europe EGFR-TKI For Advanced NSCLC Market
10.2.6.6.1 Rest of Europe EGFR-TKI For Advanced NSCLC Market by Type
10.2.6.6.2 Rest of Europe EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.2.6.6.3 Rest of Europe EGFR-TKI For Advanced NSCLC Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Overview
10.3.2 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis
10.3.3 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Therapy Type
10.3.5 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Countries
10.3.6.1 Australia EGFR-TKI For Advanced NSCLC Market
10.3.6.1.1 Australia EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.1.2 Australia EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.1.3 Australia EGFR-TKI For Advanced NSCLC Market by End User
10.3.6.2 China EGFR-TKI For Advanced NSCLC Market
10.3.6.2.1 China EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.2.2 China EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.2.3 China EGFR-TKI For Advanced NSCLC Market by End User
10.3.6.3 India EGFR-TKI For Advanced NSCLC Market
10.3.6.3.1 India EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.3.2 India EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.3.3 India EGFR-TKI For Advanced NSCLC Market by End User
10.3.6.4 Japan EGFR-TKI For Advanced NSCLC Market
10.3.6.4.1 Japan EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.4.2 Japan EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.4.3 Japan EGFR-TKI For Advanced NSCLC Market by End User
10.3.6.5 South Korea EGFR-TKI For Advanced NSCLC Market
10.3.6.5.1 South Korea EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.5.2 South Korea EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.5.3 South Korea EGFR-TKI For Advanced NSCLC Market by End User
10.3.6.6 Rest of Asia-Pacific EGFR-TKI For Advanced NSCLC Market
10.3.6.6.1 Rest of Asia-Pacific EGFR-TKI For Advanced NSCLC Market by Type
10.3.6.6.2 Rest of Asia-Pacific EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.3.6.6.3 Rest of Asia-Pacific EGFR-TKI For Advanced NSCLC Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Overview
10.4.2 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis
10.4.3 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Therapy Type
10.4.5 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa EGFR-TKI For Advanced NSCLC Market
10.4.6.1.1 South Africa EGFR-TKI For Advanced NSCLC Market by Type
10.4.6.1.2 South Africa EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.4.6.1.3 South Africa EGFR-TKI For Advanced NSCLC Market by End User
10.4.6.2 Saudi Arabia EGFR-TKI For Advanced NSCLC Market
10.4.6.2.1 Saudi Arabia EGFR-TKI For Advanced NSCLC Market by Type
10.4.6.2.2 Saudi Arabia EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.4.6.2.3 Saudi Arabia EGFR-TKI For Advanced NSCLC Market by End User
10.4.6.3 U.A.E EGFR-TKI For Advanced NSCLC Market
10.4.6.3.1 U.A.E EGFR-TKI For Advanced NSCLC Market by Type
10.4.6.3.2 U.A.E EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.4.6.3.3 U.A.E EGFR-TKI For Advanced NSCLC Market by End User
10.4.6.4 Rest of Middle East and Africa EGFR-TKI For Advanced NSCLC Market
10.4.6.4.1 Rest of Middle East and Africa EGFR-TKI For Advanced NSCLC Market by Type
10.4.6.4.2 Rest of Middle East and Africa EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.4.6.4.3 Rest of Middle East and Africa EGFR-TKI For Advanced NSCLC Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America EGFR-TKI For Advanced NSCLC Market Overview
10.5.2 South and Central America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis
10.5.3 South and Central America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Type
10.5.4 South and Central America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Therapy Type
10.5.5 South and Central America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By End User
10.5.6 South and Central America EGFR-TKI For Advanced NSCLC Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil EGFR-TKI For Advanced NSCLC Market
10.5.6.1.1 Brazil EGFR-TKI For Advanced NSCLC Market by Type
10.5.6.1.2 Brazil EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.5.6.1.3 Brazil EGFR-TKI For Advanced NSCLC Market by End User
10.5.6.2 Argentina EGFR-TKI For Advanced NSCLC Market
10.5.6.2.1 Argentina EGFR-TKI For Advanced NSCLC Market by Type
10.5.6.2.2 Argentina EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.5.6.2.3 Argentina EGFR-TKI For Advanced NSCLC Market by End User
10.5.6.3 Rest of South and Central America EGFR-TKI For Advanced NSCLC Market
10.5.6.3.1 Rest of South and Central America EGFR-TKI For Advanced NSCLC Market by Type
10.5.6.3.2 Rest of South and Central America EGFR-TKI For Advanced NSCLC Market by Therapy Type
10.5.6.3.3 Rest of South and Central America EGFR-TKI For Advanced NSCLC Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. EGFR-TKI FOR ADVANCED NSCLC MARKET, KEY COMPANY PROFILES
12.1. BETA PHARMA LTD
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ACTIZA PHARMACEUTICALS
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. SUN PHARMACEUTICALS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ROCHE
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. TEVA PHARMACEUTICAL INDUSTRIES
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ARMAS PHARMACEUTICALS, INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BOEHRINGER INGELHEIM
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. REWINE PHARMACEUTICAL
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MSN LABS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT PUBLISHERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Beta pharma Ltd
2. Actiza pharmaceuticals
3. AstraZeneca
4. Sun Pharmaceuticals
5. Roche
6. Teva Pharmaceutical Industries
7. Armas Pharmaceuticals, Inc
8. Boehringer Ingelheim
9. Rewine Pharmaceutical
10. MSN Labs
Global Electronic Colposcope Market Rese..
The research team projects that the Electronic Colposcope ma..
+1-646-791 7070US (Toll Free)